慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)

2021-04-30 中华医学会血液学分会 中华血液学杂志,2021,42(4):265-275.

慢性移植物抗宿主病(cGVHD)指异基因造血干细胞移植(allo-HSCT)后,受者在重建供者免疫的过程中,来源于供者的淋巴细胞攻击受者脏器产生的临床病理综合征(包括经典型cGVHD和重叠综合征),是

中文标题:

慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)

发布日期:

2021-04-30

简要介绍:

慢性移植物抗宿主病(cGVHD)指异基因造血干细胞移植(allo-HSCT)后,受者在重建供者免疫的过程中,来源于供者的淋巴细胞攻击受者脏器产生的临床病理综合征(包括经典型cGVHD和重叠综合征),是移植后主要并发症之一,发生率为30%~70%。cGVHD发生机制复杂,临床表现多样,个体差异大,病程迁延持久,如不规范诊治,轻则影响患者生活质量,重则影响远期生存。随着移植技术体系的不断完善,患者对移植后生活质量的诉求越来越高,重视cGVHD的防治非常重要。在参考国内外该领域指南/共识和相关研究进展后制定本共识,旨在为cGVHD的规范化诊疗提供参考。

下载附件:

(因为版权问题,不支持下载)

评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2107687, encodeId=58d3210e687a0, content=学习<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Tue Dec 27 16:18:09 CST 2022, time=2022-12-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1206390, encodeId=f38f1206390c4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211016/399b012e115a4068af39569b4e0293bf/e037eaf8238a4b04a97cc89aff582179.jpg, createdBy=68785617972, createdName=ms2000000178642872, createdTime=Sun Mar 27 16:16:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071051, encodeId=022f10e105162, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6ee5481802, createdName=ms6000000918490999, createdTime=Wed Nov 17 10:59:31 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056530, encodeId=57e81056530e1, content=这个可以看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:29:19 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012692, encodeId=2f3b10126929a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/9baf3e1da43c45918a4d854bbd4d4b75/44302de863dc4a359d7bc80266c4d9ba.jpg, createdBy=fa565140002, createdName=14674335m17暂无昵称, createdTime=Mon Aug 30 00:02:30 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2022-12-27 14775a26m11暂无昵称 来自四川省
  2. [GetPortalCommentsPageByObjectIdResponse(id=2107687, encodeId=58d3210e687a0, content=学习<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Tue Dec 27 16:18:09 CST 2022, time=2022-12-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1206390, encodeId=f38f1206390c4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211016/399b012e115a4068af39569b4e0293bf/e037eaf8238a4b04a97cc89aff582179.jpg, createdBy=68785617972, createdName=ms2000000178642872, createdTime=Sun Mar 27 16:16:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071051, encodeId=022f10e105162, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6ee5481802, createdName=ms6000000918490999, createdTime=Wed Nov 17 10:59:31 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056530, encodeId=57e81056530e1, content=这个可以看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:29:19 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012692, encodeId=2f3b10126929a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/9baf3e1da43c45918a4d854bbd4d4b75/44302de863dc4a359d7bc80266c4d9ba.jpg, createdBy=fa565140002, createdName=14674335m17暂无昵称, createdTime=Mon Aug 30 00:02:30 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2022-03-27 ms2000000178642872

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2107687, encodeId=58d3210e687a0, content=学习<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Tue Dec 27 16:18:09 CST 2022, time=2022-12-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1206390, encodeId=f38f1206390c4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211016/399b012e115a4068af39569b4e0293bf/e037eaf8238a4b04a97cc89aff582179.jpg, createdBy=68785617972, createdName=ms2000000178642872, createdTime=Sun Mar 27 16:16:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071051, encodeId=022f10e105162, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6ee5481802, createdName=ms6000000918490999, createdTime=Wed Nov 17 10:59:31 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056530, encodeId=57e81056530e1, content=这个可以看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:29:19 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012692, encodeId=2f3b10126929a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/9baf3e1da43c45918a4d854bbd4d4b75/44302de863dc4a359d7bc80266c4d9ba.jpg, createdBy=fa565140002, createdName=14674335m17暂无昵称, createdTime=Mon Aug 30 00:02:30 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-11-17 ms6000000918490999

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2107687, encodeId=58d3210e687a0, content=学习<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Tue Dec 27 16:18:09 CST 2022, time=2022-12-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1206390, encodeId=f38f1206390c4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211016/399b012e115a4068af39569b4e0293bf/e037eaf8238a4b04a97cc89aff582179.jpg, createdBy=68785617972, createdName=ms2000000178642872, createdTime=Sun Mar 27 16:16:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071051, encodeId=022f10e105162, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6ee5481802, createdName=ms6000000918490999, createdTime=Wed Nov 17 10:59:31 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056530, encodeId=57e81056530e1, content=这个可以看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:29:19 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012692, encodeId=2f3b10126929a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/9baf3e1da43c45918a4d854bbd4d4b75/44302de863dc4a359d7bc80266c4d9ba.jpg, createdBy=fa565140002, createdName=14674335m17暂无昵称, createdTime=Mon Aug 30 00:02:30 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-09-30 13f0c37dm61暂无昵称

    这个可以看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2107687, encodeId=58d3210e687a0, content=学习<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Tue Dec 27 16:18:09 CST 2022, time=2022-12-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1206390, encodeId=f38f1206390c4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211016/399b012e115a4068af39569b4e0293bf/e037eaf8238a4b04a97cc89aff582179.jpg, createdBy=68785617972, createdName=ms2000000178642872, createdTime=Sun Mar 27 16:16:13 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071051, encodeId=022f10e105162, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6ee5481802, createdName=ms6000000918490999, createdTime=Wed Nov 17 10:59:31 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056530, encodeId=57e81056530e1, content=这个可以看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:29:19 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012692, encodeId=2f3b10126929a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/9baf3e1da43c45918a4d854bbd4d4b75/44302de863dc4a359d7bc80266c4d9ba.jpg, createdBy=fa565140002, createdName=14674335m17暂无昵称, createdTime=Mon Aug 30 00:02:30 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-08-30 14674335m17暂无昵称

    谢谢分享

    0